anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Inherited metabolic diseases (IMDs) are a group of heterogeneous genetic disorders resulting in substrate accumulation, energy deficiency, or complex molecular defects due to the failure of specific molecules to act as enzymes, cofactors, transporters, or receptors in specific metabolic pathways. The pathophysiological changes seen in IMDs are sometimes associated with intellectual disability (ID) or neurocognitive decline, necessitating multidisciplinary input. We here describe our experience at one tertiary metabolic centre in the UK. We reviewed the case prevalence and existing service provision in one adult IMD service covering a multi-ethnic population of 10 million in North England. In our cohort of 2268 IMD patients, 1598 patients had general metabolic conditions (70.5%), and 670 had lysosomal storage disease/disorders (LSD)s (29.5%). The overall prevalence of ID and neurocognitive decline was found to be 15.7% (n = 357), with patients with LSDs accounting for 23.5% (n = 84) of affected patients. Given the prevalence of ID in adults with IMDs, access to multidisciplinary input from neuropsychology and neuropsychiatry services is important. Education of healthcare professionals to diagnose IMDs in patients with ID, in addition to neurocognitive and neuropsychiatric presentations, will avoid missed diagnoses of IMD and will have a positive effect on patient outcomes.
INTUNIV is a once-daily, extended-release formulation of guanfacine hydrochloride (HCl) in a matrix tablet formulation for oral administration only. The chemical designation is N-amidino-2-(2,6-dichlorophenyl) acetamide monohydrochloride. The molecular formula is C H Cl N O·HCl corresponding to a molecular weight of 282.55. The chemical structure is: ®9923

Guanfacine HCl is a white to off-white crystalline powder, sparingly soluble in water (approximately 1 mg/mL) and alcohol and slightly soluble in acetone. The only organic solvent in which it has relatively high solubility is methanol (>30 mg/mL). Each tablet contains guanfacine HCl equivalent to 1 mg, 2 mg, 3 mg, or 4 mg of guanfacine base. The tablets also contain hypromellose, methacrylic acid copolymer, lactose, povidone, crospovidone, microcrystalline cellulose, fumaric acid, and glyceryl behenate. In addition, the 3mg and 4mg tablets also contain green pigment blend PB-1763.
This protocol involves an 8-week, open-label, pilot study evaluating the effectiveness, safety, and tolerability of Ritalin LA in treating Attention-Deficit/Hyperactivity Disorder (ADHD) in 4 and 5 year old children. The purpose of this study is to ascertain pilot data on the use of long-acting stimulants in preschool-age children since virtually no data exist on these medications in this population. The interventions include utilizing short-acting methylphenidate for the initial dosing and titration and then converting the children to Ritalin LA once an optimal dose has been found. Parents will also be receiving parent education training throughout the study. Evaluations will include obtaining the ADHD-IV at every visit, side effects of the medication, vital signs, EKG, physical exam, the Clinical Global Assessment Scale, and the Clinical Global Impression-Improvement and Severity Scales. This study will also assess parent stress with the Parent Stress Index and the emotional index of the children with the Expressed Emotion Scale for Children. Follow-up will be weekly during the first month and bi-weekly during the second month.
BACKGROUND: Gestational weight gain (GWG) is a routinely monitored aspect of pregnancy health, yet critical gaps remain about optimal GWG in pregnant people from socially marginalized groups, or with pre-pregnancy body mass index (BMI) in the lower or upper extremes. The PROMISE study aims to determine overall and trimester-specific GWG associated with the lowest risk of adverse birth outcomes and detrimental infant and child growth in these underrepresented subgroups. This paper presents methods used to construct the PROMISE cohort using electronic health record data from a network of community-based healthcare organizations and characterize the cohort with respect to baseline characteristics, longitudinal data availability, and GWG.
METHODS: We developed an algorithm to identify and date pregnancies based on outpatient clinical data for patients 15 years or older. The cohort included pregnancies delivered in 2005-2020 with gestational age between 20 weeks, 0 days and 42 weeks, 6 days; and with known height and adequate weight measures needed to examine GWG patterns. We linked offspring data from birth records and clinical records. We defined study variables with attention to timing relative to pregnancy and clinical data collection processes. Descriptive analyses characterize the sociodemographic, baseline, and longitudinal data characteristics of the cohort, overall and within BMI categories.
RESULTS: The cohort includes 77,599 pregnancies: 53% had incomes below the federal poverty level, 82% had public insurance, and the largest race and ethnicity groups were Hispanic (56%), non-Hispanic White (23%) and non-Hispanic Black (12%). Pre-pregnancy BMI groups included 2% underweight, 34% normal weight, 31% overweight, and 19%, 8%, and 5% Class I, II, and III obesity. Longitudinal data enable the calculation of trimester-specific GWG; e.g., a median of 2, 4, and 6 valid weight measures were available in the first, second, and third trimesters, respectively. Weekly rate of GWG was 0.00, 0.46, and 0.51 kg per week in the first, second, and third trimesters; differences in GWG between BMI groups were greatest in the second trimester.
CONCLUSIONS: The PROMISE cohort enables characterization of GWG patterns and estimation of effects on child growth in underrepresented subgroups, ultimately improving the representativeness of GWG evidence and corresponding guidelines.
A mobile device and a server exchange information in response to the mobile device detecting a proximity beacon. Upon detecting the proximity beacon, the mobile device initiates a web service call to the server. A mobile device user will indicate a choice whether to opt-in upon registration. If the user has opted in, the server will retrieve additional information about the user including prescription information. The server will transmit prescription information and other marketing information to the mobile device. The server may be configured to receive additional information from the mobile device, for example, a request for a prescription to be refilled.
Pigments are used to impart color in finished products. The performances of pigments can be improved by coating with suitable materials rendering suitable properties. For cosmetic applications the pigments are usually surface treated with hydrophobizing material rendering the pigments hydrophobic. This invention relates to the use of polyhydroxy fatty acid preferably dihydroxysteadc acid (DHSA) and/or metallic salts of dihydroxystearic acid (Metallic DHSA) to coat pigments in particular pigments to be used in color cosmetic formulations. DHSA is produced either from crude or refined oleic acid or via chemical transformation or biotransformation of suitable substrates, used either in crude or refined form and the metallic salts are produced either using crude or refined DHSA, DHSA and Metallic DHSA are used to coat pigments and when these coated pigments are incorporated into finished products formulations such as cosmetic formulations, enhanced performances are observed. In color cosmetics the enhanced performances include enhancing skin adhesion, better spreadability, increasing strength of the stick, increasing apparent size and increased hydrophobicity of make-up cosmetics such as lipsticks, foundations, mascaras, eye shadows etc.
In this arm, patients will undergo stenting immediately after balloon angioplasty. After stent implantation, microvascular flow / resistance values will be continuously monitored using pressure/flow sensor tipped guide wire until the end of 1 hour follow up period.
Follicle-stimulating cosmetic lotion that regenerates the keratin and manufacturing process. The cosmetic lotion has been prepared from rosa damascena (turkish rose), rosmarinus officinalis (rosemary), aloe barbadensis (aloe vera), urtica urens (small nettle), cucumis sativus (cucumber), salvia officinalis (sage), sambucus nigra (elderberry), water and alcohol. For its manufacture is cooked separately in water, each of the plants, then a mixture of all of them is made and allowed to stand, finally alcohol is added. This cosmetic lotion strengthens existing hair, provides shine, volume and life, reduces dandruff and hyperseborrhea of the scalp, stimulates the hair follicles for the birth of new hair, prevents the fall, strengthens, gives shine and flexibility to the nails, regenerates the cornea layer of the cornea of the eye, (improving vision, both night and daytime) and the epidermis making it more resistant to external agents. Stops and recovers hearing loss. (Machine-translation by Google Translate, not legally binding)
Products for altering IL-33 activity including antibodies that specifically bind to an epitope with the polypeptide sequence of IL-33 such as antibodies that specifically bind to a protease cleavage region of IL-33 comprising the amino acid sequence of SEQ ID No. 17, or SEQ ID NO. 16, or SEQ ID NO. 10; isolated IL-33 polypeptide(s); and compositions comprising a soluble IL-33 receptor linked to an enzyme capable of cleaving IL-33 or an antibody that binds to IL-33 linked to an enzyme capable of cleaving IL-33.  The invention also relates to methods of altering IL-33 activity using the products described herein.  <Figure 22>
The invention relates to a commodity, in particular to a smoking-quitting tooth paste containing biological active factors. The invention is formed by the following materials according to weight proportions: 1 to 2 of arece, 2 to 1 of mint, 10 to 30 of gingkgo extracts, 1 to 5 of liquorice extracts and 10 to 100 tooth paste base. The invention adopts the tooth paste as a carrier to carry out a smoking-quitting therapy in the everyday tooth-brushing process, which is easy for operation. The invention is made by pure Chinese herbal medicines with proper proportion and low toxic and side effect. The effect of the biological active factors for smoking-quitting is reliable and quick and clinic symptoms can disappear quickly with distinct therapy effect. After the cure, re-smoking can be avoided. The invention is suitable for smokers of different ages and systems and has wide application range. People who smoke by using the invention can quit smoking while people who do not smoke use the invention can prevent smoking. The invention is safe, reliable and effective. By using the invention, tooth-cleaning and smoking-quitting can be realized by one time with double effect of tooth-cleaning and smoking-quitting.
The invention relates to a method for producing a purified recombinant TSH receptor preparation (rTSHR preparation). According to said method, a recombinant fusion-TSH-receptor is produced with an additional amino acid sequence inserted between the amino acid sequence of the functional TSH-receptor and a peptide residue which can be bonded to a solid phase. Said additional amino acid sequence can be selectively split off from the amino acid sequence of the functional TSH-receptor using a suitable protease, e.g., factor Xa. The fusion receptor is bonded to a suitable solid phase, washed to remove contaminant constituents and optionally marked in bonded form. The fusion receptor which is bonded to the solid phase is treated with protease to proteolytically split off the amino acid sequence of the functional TSH-receptor from the solid phase-bound residue of the fusion receptor and the resulting purified rTSHR preparation is prepared. The purified or purified and marked human rTSHR preparation can be used for oral toleration and for producing a novel immunoprecipitation assay for analysing anti-TSHR auto-antibodies.
This study aimed to compare newly developed diabetes-specific complete smoothie formulas with a standard diabetes-specific nutritional formula (DSNF) regarding their effects on glucose homeostasis, insulin levels, and lipid metabolism in obese type 2 diabetes (T2DM) patients. We conducted a randomized, double-blind, crossover study with 41 obese T2DM participants to compare two developed diabetes-specific complete smoothie formulas, a soy-based regular smoothie (SM) and a smoothie with modified carbohydrate content (SMMC), with the standard DSNF, Glucerna. Glycemic and insulin responses were assessed after the participants randomly consumed 300 kilocalories of each formulation on three separate days with a 7-day gap between. Postprandial effects on glycemic control, insulin levels, and lipid metabolism were measured. SMMC resulted in a significantly lower glucose area under the curve (AUC0-240) compared to Glucerna and SM (p < 0.05 for both). Insulin AUC0-240 after SMMC was significantly lower than that after SM and Glucerna (p < 0.05). During the diets, the suppression of NEFA was more augmented on SM, resulting in a less total AUC0-240 of NEFA compared to the SMMC diet (p < 0.05). C-peptide AUC0-240 after SMMC was significantly lower than that after Glucerna (p < 0.001). Conversely, glucagon AUC0-240 after SMMC was significantly higher than that after SM and Glucerna (p < 0.05). These results highlight SMMC as the better insulin-sensitive formula, potentially achieved through increased insulin secretion or a direct reduction in glucose absorption. The unique composition of carbohydrates, amino acids, and fats from natural ingredients in the smoothies may contribute to these positive effects, making them promising functional foods for managing diabetes and obesity.
PROBLEM TO BE SOLVED: To obtain the subject preparation improved in rough skin preventive and remedying effect by including a specific acetylated hyaluronic acid and an α-hydroxyacid (salt) in specified proportions. SOLUTION: This preparation is obtained by formulating (A) 0.0001-10 wt.% of an acetylated hyaluronic acid pref. 10,000-1,000,000 in molecular weight in terms of hyaluronic acid and 2-4 in the number of substitution of acetyl groups per hyaluronic acid constitutive unit, (B) 0.001-10 wt.% of an α-hydroxyacid (salt) so as to be (100:1) to (1:10,000) in the weight ratio A/B, and (C) as necessary, ultraviolet light absorber, oil, moisturizer, antioxidant, surfactant, activator, perfume, water, color, etc. The ingredient A is formed, for example, by dispersing powdery hyaluronic acid in acetic acid followed by reaction in the presence of trifluoroacetic anhydride as catalyst. The ingredient B is pref. lactic acid, tartaric acid, citric acid or glycolic acid.
Block randomization will be used to randomize patients to one of two combinations. Group A will receive capsules containing 650 mg Acetaminophen plus 400 mg Ibuprofen. Group B will receive capsules containing 600 mg Acetaminophen, 15 mg caffeine and 60 mg codeine. Capsules are placed in identical dossettes containing a seven day supply. Patients are instructed to start taking their medications post-op and continue until they are pain free. All participants are given a series of blank Visual Analogue scales and Likert scales and instructed to record their level of pain intensity and pain relief four times per day for the entire week. Peri-operative pain management will be standardized. Patients will not receive pre-operative analgesics. Intra-operative analgesia will be intravenous opioids as selected by anaesthesiology. No local/regional anaesthesia will be used. Intravenous ketorolac will not be allowed for trial participants. All patients will receive intravenous opioid and anti-emetic if required in PACU. Any patients with peri-operative complications or other problems requiring admission or alternative analgesics will be excluded.
Subjects will receive 48 weeks (12 four-week cycles) of crizotinib 250 mg PO twice a day (BID). Subjects will be evaluated by routine bloodwork and physical exam every 4 weeks while they are receiving crizotinib and during follow up period.
The present invention pertains to a compound that has an excellent retinoic acid receptor-related orphan receptor γt inhibitory effect, or a pharmaceutically acceptable salt thereof. Provided is a compound represented by general formula (I), or a pharmaceutically acceptable salt thereof. (In the formula, R 1  is a C 1 -C 6  alkyl group, a C 3 -C 6  cycloalkyl group, or a phenyl group. R 2  is a hydrogen atom, a halogen atom, a C 1 -C 6  alkyl group, or the like. R 3  is a hydrogen atom, a C 2 -C 7  carboxyalkyl group, or a hydroxyl group. R 4  is a halogen atom or a C 1 -C 6  alkyl group. R 5  is a hydrogen atom or a C 1 -C 6  alkyl group. R 6  is a hydrogen atom, a halogen atom, or a C 1 -C 6  alkyl group. R 7  is a hydrogen atom, a halogen atom, or the like. R 8  is a hydroxyl group, a C 1 -C 6  alkoxy group, a mono-C 1 -C 6  alkylamino group, or the like. L is a single bond, a methylene group, or an oxygen atom. E is a phenylene group optionally substituted independently with one or two groups selected from halogen atoms, C 1 -C 6  alkyl groups, and C 1 -C 6  alkylsulfonyl groups, or the like. Q 1  is a nitrogen atom or a group represented by the formula =CH—. Q 2  is a nitrogen atom or a group represented by the formula =CH—. The group represented by the formula —U—T— is a group represented by the formula —CH 2 —CH 2 — or the like. Y is a methylene group or an oxygen atom. V is a nitrogen atom or a group represented by the formula =C(R 9 )—. R 9  is a hydrogen atom, a C 1 -C 6  alkyl group, or the like.)
Risk Summary

Based on findings in animals and its mechanism of action [see Clinical Pharmacology (12.1)], VENCLEXTA may cause embryo-fetal harm when administered to a pregnant woman. There are no available data on VENCLEXTA use in pregnant women to inform a drug-associated risk. Administration of venetoclax to pregnant mice during the period of organogenesis was fetotoxic at exposures 1.2 times the human exposure at the recommended dose of 400 mg daily based on AUC. Advise pregnant women of the potential risk to a fetus. 

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. 

Data

Animal data

In embryo-fetal development studies, venetoclax was administered to pregnant mice and rabbits during the period of organogenesis. In mice, venetoclax was associated with increased post-implantation loss and decreased fetal body weight at 150 mg/kg/day (maternal exposures approximately 1.2 times the human exposure at the recommended dose of 400 mg once daily). No teratogenicity was observed in either the mouse or the rabbit.
BACKGROUND: Atrial fibrillation (AF) represents a global epidemic. Although international AF practice guidelines indicate weight loss for patients with AF and comorbid obesity (BMI ≥ 30 kg/m2) to alleviate symptom burden and improve prognosis, few cardiac rehabilitation (CR) programs include targeted weight loss treatment.
AIMS: This RCT protocol will evaluate the efficacy of a "Small Changes" behavioral weight loss treatment (BWLT) to produce clinically relevant (≥ 10%) weight loss among patients with AF and obesity undergoing CR, relative to CR alone. Secondary aims are to establish efficacy of CR + BWLT for improving AF symptoms, AF risk factors, and health-related quality of life.
METHODS: Adults (18 +) with AF and obesity will be recruited and randomized to receive CR + BWLT (intervention) or CR-only (control). Controls will receive CR consisting of supervised exercise and risk factor self-management for 12 weeks. The intervention group will receive CR plus BWLT (12 weekly, group-based virtual sessions, followed by 12 weeks of follow-up support). Weight and AF-risk factors will be assessed at pre-randomization, 12 weeks, 24 weeks, and 52 weeks. AF burden will be assessed using 30-s ECGs recorded bidaily and with AF symptoms. The primary endpoint of weight loss will be calculated from baseline to 52 weeks as a percentage of starting weight. Intention-to-treat analyses will compare the proportion in each group achieving ≥ 10% weight loss. Assuming success rates of 5% and 30% among controls and intervention groups, respectively, and a 30% loss to follow-up, 120 patients (60 per group) will provide 80% power to detect a difference using a two-sided independent test of proportions (alpha = 5%).
IMPACT: This clinical trial will be the first to demonstrate that adding BWLT to CR promotes clinically meaningful weight loss among patients with AF and comorbid obesity. Findings will inform design and execution of a large efficacy trial of long-term (e.g., 5-year) clinical endpoints (e.g., AF severity, mortality). Implementing weight control interventions designed to target the AF substrate in CR could dramatically reduce morbidity and enhance quality of life among patients living with AF in Canada.
TRIAL REGISTRATION: ClinicalTrials.gov registration number: NCT05600829. Registered October 31, 2022.
We investigated the protective effect of walnut peptides and YVPFPLP (YP-7) on scopolamine-induced memory impairment in mice and β-amyloid (Aβ)-induced excitotoxic injury in primary hippocampal neurons, respectively. Additionally, the protective mechanism of YP-7 on neuronal excitotoxicity was explored. Mouse behavioral and hippocampal slice morphology experiments indicate that YP-7 improves the learning and memory abilities of cognitively impaired mice and protects synaptic integrity. Immunofluorescence, western blotting, and electrophysiological experiments on primary hippocampal neurons indicate that YP-7 inhibits neuronal damage caused by excessive excitation of neurons induced by Aβ. HT-22 cell treatment with peroxisome proliferator-activated receptor γ (PPARγ) activators and inhibitors showed that YP-7 activates PPARγ expression and maintains normal neuronal function by forming stable complexes with PPARγ to inhibit the extracellular regulated protein kinase pathway. Therefore, YP-7 can ameliorate glutamate-induced excitotoxicity and maintain neuronal signaling. This provides a theoretical basis for active peptides to ameliorate excitotoxicity and the development of functional foods.
Individualize the dosage of metoprolol succinate extended-release. The usual initial dosage is 100 mg daily, given in a single dose. Gradually increase the dosage at weekly intervals until optimum clinical response has been obtained or there is a pronounced slowing of the heart rate. Dosages above 400 mg per day have not been studied. If treatment is to be discontinued, reduce the dosage gradually over a period of 1 to 2 weeks [see Error! Hyperlink reference not valid.].
A method of treating avascular necrosis ('AVN') comprising administering one or more osteoinductive formulations to the site of AVN disease progression. The method involves the combination of a core decompression technique, followed by the introduction of one or more osteoinductive formulations into the decompression core, and concluding with capping of the ateral aspect of the decompression core with a femoral core cap. The osteoinductive formulations of the invention comprise one or more osteoinductive agents and suitable carrier molecules. The femoral core cap retains the osteoinductive formulation within the decompression core, thereby preventing leakage of the osteoinductive formulation from the decompression core. The method of the invention optionally comprises introduction of autograft or allograft with the osteoinductive formulations of the invention. The method of the invention further optionally comprises incorporation of sustained release compositions to provide extended periods of osteogenesis.